Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Screening people with diabetes for eye damage using artificial intelligence

Studies an AI tool to screen adults with diabetes for diabetic retinopathy, an eye disease.

Plain-language title generated from the registry record
Registry title: The Diabetic Retinopathy Screening, Prevention and Control Program

Key facts

Where
Shanghai, ChinaSee the 2 sites

Where in China

  • Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
  • Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Shanghai Jiao Tong University School of Medicine
Trial code
NCT04240652
Record updated
5 February 2020
Original description
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.Read full original descriptionShow less

The Diabetic Retinopathy Screening, Prevention and Control Program

The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.

Inclusion: Meet the diagnostic criteria for type 2 diabetes according to the World Health Organization (WHO) in 1999; Type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, Cushing's syndrome, thyroid dysfunction, or acromegaly; Subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study.

Exclusion: Those who have a history of drug abuse; Sexually transmitted diseases such as AIDS and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase; Any condition that the investigator think that the subject is not suitable for participating in the study; For detailed In-/Ex-clusion criteria please see the study protocol.

ClinicalTrials.gov NCT04240652